Long-term tolerability and safety of darifenacin demonstrated in a 2-year extension study in patients with overactive bladder
Steers W1, Dwyer P2, Gittelman M3, Lheritier K4, Kawakami F4 1. University of Virginia Health System, Charlottesville, VA, USA, 2. Mercy Hospital for Women, Melbourne, Australia, 3. South Florida Medical Research, Aventura, FL, USA, 4. Novartis Pharma AG, Basel, Switzerland
|
|
Abstract 141
|
|
|
Non Discussion Posters
Scientific Non Discussion Poster Session 17
|
|
|